Ocular Hypertension Market to Reach $9.37 Billion by 2035 as Sustained-Release Therapies Gain Ground
Updated
Updated · BioSpace · Jun 23
Ocular Hypertension Market to Reach $9.37 Billion by 2035 as Sustained-Release Therapies Gain Ground
1 articles · Updated · BioSpace · Jun 23
Summary
$9.37 billion is the projected global ocular hypertension market size for 2035, up from $4.65 billion in 2026, implying an 8.10% annual growth rate.
Sustained-release intraocular pressure therapies and fixed-dose combination drugs are driving the expansion as treatment shifts away from daily eye drops toward longer-acting delivery systems that improve adherence.
North America held the largest 2025 share at 42.5%, supported by specialized ophthalmic pipelines, drug-device innovation and favorable reimbursement, while Asia-Pacific is forecast to grow fastest on aging demographics and broader screening.
Medical treatment accounted for 70% of the market in 2025, topical therapies held 78%, and retail pharmacies led distribution with 45%, though surgical treatments and hospital-and-clinic channels are expected to expand faster.
High costs for implants, surgeries and advanced biopharmaceuticals remain a key constraint even as AI diagnostics, Minimally invasive glaucoma surgery, nanomedicine and gene-editing approaches broaden the market's long-term outlook.